Skip to main content

PEPIDH1M vaccine + vorasidenib

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

  • RegistryNCT05609994
  • PhasePhase 1
  • StatusRecruiting
  • ConditionLow Grade Glioma of Brain
  • SponsorKaty Peters, MD, PhD
How ViCToRy worksNCT056099941 min

What the film says

Read the transcript

This trial is for recurrent IDH1 mutant lower grade glioma, a brain tumor, in adults at the first recurrence.

The idea: pair two treatments. Vorasidenib, a daily pill taken for up to 14 four week cycles, blocks the mutant IDH1 and IDH2 enzymes. After two cycles, a tumor specific peptide vaccine is added, given under the skin. Servier is listed as a collaborator.

The trial plans 48 patients and begins with a safety lead-in. At Duke University in Durham, Katherine Peters leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05609994

    Recurrent IDH1 mutant lower grade glioma, a brain tumor, in adults at first recurrence; Vorasidenib is a daily pill that blocks mutant IDH1 and IDH2 enzymes; After two cycles, a tumor specific peptide vaccine is added, given under the skin; Servier is listed as a collaborator (+2 more lines)

The drug

What is being tested.

Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15.

This study is designed to assess the safety and efficacy of the PEPIDH1M vaccine in combination with vorasidenib in adult patients recurrent IDH1 mutant lower grade gliomas. Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Patients will then receive vorasidenib 40 mg orally once a day for 28 days.

The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid (1 flocculation unit [Lf] in a total volume of 0.4 mL saline).

The study

How the trial runs.

The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • IDH1R132H expression in primary tumor
  • Clinical and/or radiographic, progressive Grade 2-3 glioma with greater than 2 cm of non-enhancing disease in one plane.
  • 1st recurrence only
  • Signed informed consent
  • For females of child-bearing potential, negative serum pregnancy test at screening
  • Women of childbearing potential and male participants must agree to practice contraception

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.